Effects, of intravenous prostaglandin E1 on arterial compliance:: a randomized controlled trial

被引:2
|
作者
Mlekusch, W [1 ]
Schillinger, M [1 ]
Sabeti, S [1 ]
Al-Awami, M [1 ]
Gschwandtner, M [1 ]
Minar, E [1 ]
机构
[1] Vienna Gen Hosp, Sch Med, Dept Angiol, A-1090 Vienna, Austria
来源
VASA-JOURNAL OF VASCULAR DISEASES | 2004年 / 33卷 / 03期
关键词
peripheral arterial disease; prostanoids; arterial compliance;
D O I
10.1024/0301-1526.33.3.131
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Prostanoids are in widespread use for the treatment of critical limb ischemia and are suggested to improve arterial compliance. However, dose- and time-dependency of these drug effects are indeterminate. We investigated the influence of intravenous application of prostanoids on arterial compliance parameters in patients with critical limb ischemia due to peripheral artery disease (PAD). Patients and methods: We included 82 consecutive patients with PAD Fontaine stage III and IV in a patient-blinded, randomized controlled trial. Patients were randomly assigned to either single dose intravenous treatment with 40 mug (n = 29) or 60 mug (n = 27) of Alprostadil (PGE) in 2.50 ml 0.9% saline over 2 hours, or 250 nil 0.9% saline solution as a placebo group (n = 26). Large and small artery compliance was measured by peripheral pulse contour analysis at base line, at one hour during intravenous infusion of Alprostadil, immediately after and 24 hours after the end of the infusion. For study purpose the patients received Alprostadil only once during the observation period of 2 days. Results: Large artery compliance, blood pressure, heart rate and cardiac output were unaffected by PGE administration irrespectively of drug-dosage or time interval. Small artery compliance increased at I hour during intravenous application of Alprostadil (40 mug Alprostadil p = 0.001; 60 mug Alprostadil p < 0.0001) compared to placebo and increased median +47% (IQR +5% to +100%) after administration of 40 mug Alprostadil and median +32% (IQR -11% to +88%) after 60 mug Alprostadil (p = 0.5). Immediately after the end of Alprostadil infusion small artery compliance decreased to baseline levels. Conclusions: Prostaglandin E-1 causes a significant improvement of small artery compliance during the time of intravenous application. However this effect rapidly diminishes after the end of administration and no dose-dependency between 40 mug and 60 mug Alprostadil is observed.
引用
收藏
页码:131 / 136
页数:6
相关论文
共 50 条
  • [1] Effects of prostaglandin E1 metabolites on the induction of arterial thromboresistance
    Sinzinger, H
    Neumann, I
    O'Grady, J
    Rogatti, W
    Peskar, BA
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 1998, 55 (5-6): : 265 - 275
  • [2] Clinical and haemostatic effects of intravenous prostaglandin E1 therapy in patients with peripheral arterial occlusive disease
    Trifiletti, A
    Scamardi, R
    Pizzoleo, MA
    Sottilotta, G
    Soraci, S
    Attina, A
    Bagnato, L
    Barbera, N
    PANMINERVA MEDICA, 1999, 41 (01) : 15 - 17
  • [3] Effects of intravenous administration of prostaglandin E1 and lipo-prostaglandin E1 on cochlear blood flow in guinea pigs
    Nishimura, T
    Nario, K
    Hosoi, H
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2002, 259 (05) : 253 - 256
  • [4] Effects of intravenous administration of prostaglandin E1 and lipo-prostaglandin E1 on cochlear blood flow in guinea pigs
    Tadashi Nishimura
    Kazuhiko Nario
    Hiroshi Hosoi
    European Archives of Oto-Rhino-Laryngology, 2002, 259 : 253 - 256
  • [5] Beneficial effects of intra-arterial and intravenous prostaglandin E1 in intestinal ischaemia-reperfusion injury
    San Norberto Garcia, Enrique Maria
    Henry Taylor, James
    Cenizo, Noelia
    Vaquero, Carlos
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2014, 18 (04) : 466 - 474
  • [6] The efficacy of intravaginal prostaglandin E1 (misoprostol) on pregnancy rates after intrauterine inseminations:: a randomized controlled trial
    Brown, SE
    Schnorr, JS
    Oehninger, S
    Kellam, K
    Gibbons, WE
    Muasher, SJ
    Toner, JP
    HUMAN REPRODUCTION, 1999, 14 : 30 - 31
  • [7] Prostanoids for chronic critical leg ischemia -: A randomized, controlled, open-label trial with prostaglandin E1
    Belgrano, EA
    Guala, A
    Mazzucchetti, S
    Marinoni, V
    Calzoni, D
    Bedoni, P
    Confalonieri, MA
    Agus, GB
    Mondani, P
    De Angelis, R
    Biasi, GM
    Piglionica, MR
    Abbritti, F
    Agrifoglio, G
    Costantini, A
    Della Vedova, MR
    Miglierina, L
    Marrocu, R
    Bragherio, G
    Zanoni, CE
    Borin, F
    Alderi, G
    Emanuelli, G
    Colzani, M
    Ponti, GB
    Berra, S
    Bevilacqua, A
    Bocca, M
    Invernizzi, C
    De Angelis, E
    Tacconi, A
    D'Angelo, F
    Vaghi, M
    Arzini, A
    Boccalon, L
    Losapio, GM
    Ambrosi, R
    Briolini, F
    Inzoli, MR
    Lombardi, G
    Tarantola, P
    Zocca, N
    Tenchini, P
    Fontanili, M
    Guidetti, D
    Pedeferri, G
    Bordoni, MC
    Catalano, A
    Visconti, W
    Vedovato, F
    ANNALS OF INTERNAL MEDICINE, 1999, 130 (05) : 412 - +
  • [8] Effects of prostaglandin E1 on reperfusion injury patients A meta-analysis of randomized controlled trials
    Zhu, Houyong
    Xu, Xiaoqun
    Ding, Yu
    Zhou, Liang
    Huang, Jinyu
    MEDICINE, 2017, 96 (15)
  • [9] EFFECTS OF PROSTAGLANDIN E1 ON MICROCIRCULATION
    WEINER, R
    KALEY, G
    FEDERATION PROCEEDINGS, 1968, 27 (02) : 282 - &
  • [10] CARDIOVASCULAR EFFECTS OF PROSTAGLANDIN E1
    NAKANO, J
    MCCURDY, JR
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1967, 156 (03): : 538 - &